Raul Huerta

Comprehensive management of the B2B business unit at both regional and global levels. Lead generation and revenue growth: Prospected, negotiated and closed projects in private market over $15 million USD. Innovative business model design: Adapted business models to strengthen regional commercial partnerships. Private market analysis: Evaluated market opportunities for products nearing patent expiration to secure post-patent commercialization licenses. Strategic alliance management: Built and maintained strong relationships with key directors and senior managers. Led end-to-end supply chain execution: From purchase order intake to final product delivery.

Managed CNS portfolio, achieving USD $8 million mxp revenue. Commercial & Marketing Strategies to increase market penetration and retain key accounts. Strengthened KOLs, KDMs and patient-medical associations relationships and brand visibility.

Design and development of IT solutions, Reactivate digital communication services for the health industry, Develop institutional relationships with target groups (pharmaceuticals, medical devices doctors, hospitals, associations, others), Market creation and customer portfolio, Business model design, Coaching transition for services and digital medical promotion.

• Development and defense of markets FY 2019 (9 million usd), • Development and defense of markets FY 2018 (6 million usd), • Liaison with different stakeholders of the private initiative, government, institutions, NGOs, etc, • Design and implementation of strategies regarding electromobility, electric motors, electrical installations and energy efficiency, solar water heating systems, • Management of communication and institutional awareness campaigns, • Multidisciplinary and institutional groups management,

Managed clean energy projects (electricity, gas, wind power, and electromobility), focused on copper use in sustainable infrastructure and energy systems.

Marketing strategies for medical devices Commercial and inbound strategies adoption, Nationawide alliances with KOL, KDM, Key stakeholders Corporate image & CME events improvement, Good practices and corporate compliance implementation

Ensure the immunoglobulin and orphan drug brand equity, Promote PID medical networks and diagnostic centers to boost Mexico´s PID record (FY2016, 1200 ID patients), Strengthen strategic alliances with medical societies, doctors, nurses, distributors, hospitals and key institutions, Ensure product availability in public and private hospitals and institutions. Higlobin relaunch for FY 2014 (7 million usd), Immunoglobulin Annual Sales target FY 2014 (22 million usd) Hizentra launch (FY2015),

Achieved FY 2014 ($22 mio USD) & 2015 ($25 mio USD) sales targets. Regional relaunch of IVIg/Higlobin (USD $7M). Regional launch of SCIg/Hizentra (USD $1.5M). Marketing plan development focused on awareness, diagnosis, and product positioning.